- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03575598
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, open-label, non-randomized, pre-operative window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative Sitravatinib and Nivolumab. A total of 12 patients who are evaluable for correlative studies, are planned for enrollment.
This study will involve treatment with Sitravatinib and Nivolumab, tests and procedures done for safety and the collection of blood samples for biomarker research. Tissue samples (fresh biopsy or archival tissue) will also be collected for biomarker research and evaluation.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed written and voluntary informed consent.
- Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- Age > 18 years, male or female.
- Patient must be diagnosed with histologically confirmed squamous cell carcinoma of the oral cavity (SCCOC) (floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, retromolar trigone and hard palate) previously untreated, considered resectable by the head and neck treating surgeon (T2-4a, N0-2, or T1 - greater than 1 cm - N2, M0; without evidence of distant metastasis).
- Patient must be willing and able to provide 2 fresh tumor biopsies for histopathological and biomarker evaluation: one at baseline and one after treatment with Sitravatinib but prior to treatment with Nivolumab. Archival tissue sample will be requested if available.
- No anti-neoplastic treatment is allowed between the time from obtaining baseline tumor specimen and enrollment.
- ECOG performance status 0-1.
Patient must have adequate organ function as determined by the following:
• Renal function: i. Serum creatinine < 1.5 ULN (upper limit of normal range) or a calculated creatinine clearance of > 50mL/min using the following formula:
Creatinine clearance = [(140-age) x wt (kg) x Constant*] / creatinine (umol/L)
*Constant = 1.23 for men, and 1.04 for women
• Bone marrow function (without hematopoietic growth factors or transfusion): i. Absolute neutrophil count (ANC) > 1.0 x 109/L ii. Leukocytes > 2.0 x 109/L iii. Hemoglobin > 90 g/L or > 9g/dL iv. Platelets > 100 x 109/L
• Liver function: i. Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN for patients with Gilbert Syndrome. ii. Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) < 2.5 x ULN
• Cardiac function: i. A normal left ventricular ejection fraction (LVEF) of ≥50% by a MUGA scan performed within 4 weeks of the study commencement.
Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). Women of child-bearing potential (WOCBP) or men whose partner is a WOCBP agrees to use contraception while participating in this study, and for a period of 6 months following termination of study treatment.
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
Primary site of head and neck carcinoma unknown, lip, skin, or outside the oral cavity.
• Patients with tumors that invade major vessels or are within ≤ 3 mm of the carotid artery as shown unequivocally by imaging studies.
- Patients with any prior history of clinically significant bleeding related to the current head and neck cancer.
- Patients with a history of gross hemoptysis (bright red blood of ½ teaspoon or more per episode of coughing) < 3 months prior to enrollment.
- Prior or concurrent radiation therapy to tumor at site of planned resection.
Any concurrent chemotherapy, biologic, immunologic or hormonal therapy for cancer treatment.
• Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.
Current or prior use of immunosuppressive medication within 14 days prior to starting dosing. The following are exceptions to this criteria:
- Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).
- Adrenal replacement steroid > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
- Steroids as premedication for hypersensitivity reactions (eg, computed tomography scan premedication).
Active or documented history of autoimmune disease within 2 years before screening, including:
- Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis).
- Patients with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, Grave's disease, Hashimoto's disease, or psoriasis not requiring systemic steroids and/or immunosuppressive agents within the past 2 years, are not excluded.
- History of primary immune deficiency.
- History of stroke or transient ischemic attack within the previous 6 months.
- History of uncontrolled hypertension (> 150 mm Hg systolic or > 100 mm Hg diastolic) on multiple observations despite standard of care treatment.
Any of the following cardiac abnormalities:
- Unstable angina pectoris,
- Congestive heart failure ≥ NYHA Class 3,
- QTc >480 milliseconds,
- Left ventricular ejection fraction (LVEF) < 50.
- Concomitant medication known to cause prolonged QT that cannot be discontinued or changed to a different medication prior to enrollment.
- History of organ transplant that requires use of immunosuppressive medications.
- Known allergy or reaction to any components of Sitravatinib and/or Nivolumab formulation.
- Subjects who are known to be human immunodeficiency (HIV) positive.
Has a known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).
- HBV DNA must be undetectable and HBsAg negative at Screening Visit.
- Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.
- Female patients who are pregnant or breast-feeding.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active clinically significant infection requiring parenteral antibiotics, unstable cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events from Sitravatinib or Nivolumab, or compromise the ability of the subject to give written informed consent.
- Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.
- Any previous treatment with a PD1 or PD-L1 inhibitor, including Nivolumab.
History of another primary malignancy, except for:
- Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study drug and of low potential risk for recurrence,
- Adequately treated non-melanoma skin cancer without evidence of disease,
- Adequately treated carcinoma in situ without evidence of disease.
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study medications.
- Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sitravatinib and Nivolumab
Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days. Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study. |
Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
Other Names:
Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic and immune effects of pre-operative therapy with Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Tumor PD-L1 expression by IHC
|
2 years
|
Pharmacodynamic and immune effects of pre-operative therapy with Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Density of immune cell population in the tumor and/or peripheral blood, including circulating tumor DNA (ctDNA), T-cell subsets, NK cells and myeloid-derived cell subsets
|
2 years
|
Pharmacodynamic and immune effects of pre-operative therapy with Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Serum pro-inflammatory cytokines and chemokines
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of pre-operative therapy with Sitravatinib and Nivolumab on patients with SCCOC
Time Frame: 2 years
|
Toxicities as per NCI CTCAE v5.0
|
2 years
|
Safety and tolerability of pre-operative therapy with Sitravatinib and Nivolumab on patients with SCCOC
Time Frame: 2 years
|
Rate of completion of surgery within the initially planned window
|
2 years
|
Safety and tolerability of pre-operative therapy with Sitravatinib and Nivolumab on patients with SCCOC
Time Frame: 2 years
|
Rate of post-operative complications
|
2 years
|
Pre-operative clinical activity of the combination of Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Rate of disease progression as per RECIST v1.1 during the pre-operative treatment period
|
2 years
|
Pre-operative clinical activity of the combination of Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Pathologic treatment effect in tumor and/ or lymph nodes
|
2 years
|
Pre-operative clinical activity of the combination of Sitravatinib and Nivolumab in patients with SCCOC
Time Frame: 2 years
|
Rate of nodal extracapsular extension and positive margins
|
2 years
|
Sitravatinib plasma levels alone and in combination with Nivolumab.
Time Frame: 2 years
|
Analysis of plasma Sitravatinib concentration before and after Nivolumab therapy
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dynamic changes in immune cell activation and/or suppression using flow cytometry, DNA/RNA sequencing, and FACS sorting
Time Frame: 2 years
|
Additional tumor cell surface marker expression
|
2 years
|
Dynamic changes in immune cell activation and/or suppression using flow cytometry, DNA/RNA sequencing, and FACS sorting
Time Frame: 2 years
|
Flow cytometry analysis of activation markers on circulating immune cells
|
2 years
|
Dynamic changes in immune cell activation and/or suppression using flow cytometry, DNA/RNA sequencing, and FACS sorting
Time Frame: 2 years
|
Tumor and immune cell genome and transcriptome analysis
|
2 years
|
Dynamic changes in intratumoral hypoxia with pre-operative Sitravatinib and Nivolumab therapy
Time Frame: 2 years
|
Analysis of tumor 18FAZA-PET uptake patterns
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lillian Siu, MD, University Health Network, Toronto
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Mouth Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- SNOW-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Oral Cavity
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous... and other conditionsUnited States
-
Wake Forest University Health SciencesTerminatedStage I Adenoid Cystic Carcinoma of the Oral Cavity | Stage I Mucoepidermoid Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Verrucous Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingTongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Recurrent Adenoid... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminatedRecurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Salivary Gland Squamous Cell Carcinoma | Stage I Salivary Gland Cancer | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Nasopharynx and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnTongue Cancer | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Verrucous Carcinoma of the Oral Cavity | Stage IVA Verrucous Carcinoma of the Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Verrucous Carcinoma of the Oral Cavity | Stage IVA Squamous Cell Carcinoma of the Lip and Oral CavityUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditionsUnited States
-
Mitchell MachtayNot yet recruitingSquamous Cell Carcinoma of the Oral Cavity or Oropharynx
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnSquamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Squamous Cell Carcinoma of the...United States
Clinical Trials on Sitravatinib
-
BeiGeneCompletedCarcinoma, Hepatocellular | Gastric/Gastroesophageal Junction CancerChina
-
Mirati Therapeutics Inc.CompletedHepatic ImpairmentUnited States
-
BeiGeneCompleted
-
Mirati Therapeutics Inc.CompletedHealthy AdultsUnited States
-
Peking University Cancer Hospital & InstituteRecruiting
-
C. Kent Osborne, MDMirati Therapeutics Inc.WithdrawnBreast Neoplasms | Triple Negative Breast Cancer | Breast Cancer Stage IV | Breast Cancer MetastaticUnited States
-
BeiGeneWithdrawn
-
Matthew InghamMirati Therapeutics Inc.Active, not recruitingLiposarcoma | Metastatic LiposarcomaUnited States
-
Anhui Provincial HospitalHenan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...Recruiting
-
Mirati Therapeutics Inc.CompletedAdvanced CancerKorea, Republic of, United States